<p>PureTech Health PLC 贊助的 ADR（NASDAQ:PRTC - 獲取免費報告）在週二的午盤交易中下跌了 0.7%。該股票最低交易價格為 16.91 美元，最後交易價格為 16.70 美元。在午盤交易中大約交易了 900 股，較日均交易量 1,977 股下降了 54%。該股票之前的收盤價為 16.81 美元。</p>
<p>獲取 <strong>PureTech Health</strong> 警報：</p>
<h2>分析師評級變動</h2>
<p>另外，Weiss Ratings 在 10 月 8 日的研究報告中重申了對 PureTech Health 股票的 &#34;賣出（d）&#34; 評級。根據 MarketBeat.com 的數據，一位研究分析師對該股票給予了賣出評級，目前該股票的共識評級為 &#34;賣出&#34;。</p>
<p><strong>閲讀我們最新的 PRTC 股票分析</strong></p>
<h2>PureTech Health 下跌 0.7%</h2>
<p>該公司的 50 日移動平均價格為 17.09 美元，200 日移動平均價格為 17.60 美元。</p>
<h2>對 PureTech Health 的對沖基金看法</h2>
<p>大型投資者最近調整了對該股票的持有。Persistent Asset Partners Ltd 在第二季度購買了 PureTech Health 的新股份，價值 29,000 美元。Diadema Partners LP 在第二季度購買了 PureTech Health 的新股份，價值約 126,000 美元。Pentwater Capital Management LP 在第一季度將其在 PureTech Health 的股份增加了 39.2%。Pentwater Capital Management LP 目前擁有 33,560 股該公司的股票，價值 664,000 美元，此前在此期間又購買了 9,449 股。最後，Lansdowne Partners UK LLP 在第三季度購買了價值約 260,973,000 美元的 PureTech Health 新頭寸。機構投資者持有該公司 0.04% 的股票。</p>
<h2>關於 PureTech Health</h2>
<p>（獲取免費報告）</p>
<p>PureTech Health plc 從事生物技術和製藥解決方案的開發和商業化，主要在美國。該公司正在開發 LYT-100，目前處於第二階段，旨在治療特發性肺纖維化（IPF）；以及 LYT-200，一種 IgG4 單克隆抗體，目前處於 1/2 階段，針對 galectin-9 用於治療實體腫瘤和血液惡性腫瘤。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 PureTech Health</li>
<li>TSX 風險投資交易所（前身為加拿大風險投資交易所）</li>
<li>為什麼台灣半導體的 6.5% 下跌可能是一個明智的購買</li>
<li>投資於高市盈率成長股</li>
<li>RTX 在國防訂單激增時飆升至歷史新高</li>
<li>商業服務股票投資</li>
<li>聰明資金正在購買汽車供應商，而不是汽車品牌</li>
</ul>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元於 PureTech Health 嗎？</h2>
<p>在你考慮 PureTech Health 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 PureTech Health 並不在名單上。</p>
<p>雖然 PureTech Health 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

PRTC

<p>PureTech Health（納斯達克代碼：PRTC）的股票在週二的午盤交易中下跌了 0.7%，交易量顯著減少。Weiss Ratings 重申了對該股票的 “賣出” 評級。該公司的 50 日和 200 日移動平均線分別為 17.09 美元和 17.60 美元。機構投資者最近調整了他們的持股。PureTech Health 正在開發特發性肺纖維化和實體腫瘤的治療方案。分析師建議其他股票可能更值得購買</p>

<p>Shares of PureTech Health PLC Sponsored ADR (NASDAQ:PRTC - Get Free Report) dropped 0.7% during mid-day trading on Tuesday . The stock traded as low as $16.91 and last traded at $16.70. Approximately 900 shares were traded during mid-day trading, a decline of 54% from the average daily volume of 1,977 shares. The stock had previously closed at $16.81.</p>
<div class="lb-trans"><p>PureTech Health PLC 贊助的 ADR（NASDAQ:PRTC - 獲取免費報告）在週二的午盤交易中下跌了 0.7%。該股票最低交易價格為 16.91 美元，最後交易價格為 16.70 美元。在午盤交易中大約交易了 900 股，較日均交易量 1,977 股下降了 54%。該股票之前的收盤價為 16.81 美元。</p>
</div><p>Get <strong>PureTech Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>PureTech Health</strong> 警報：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Separately, Weiss Ratings reiterated a &#34;sell (d)&#34; rating on shares of PureTech Health in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日的研究報告中重申了對 PureTech Health 股票的 &#34;賣出（d）&#34; 評級。根據 MarketBeat.com 的數據，一位研究分析師對該股票給予了賣出評級，目前該股票的共識評級為 &#34;賣出&#34;。</p>
</div><p><strong>Read Our Latest Stock Analysis on PRTC</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的 PRTC 股票分析</strong></p>
</div><h2>PureTech Health Trading Down 0.7%</h2>
<div class="lb-trans"><h2>PureTech Health 下跌 0.7%</h2>
</div><p>The firm's 50-day moving average price is $17.09 and its 200-day moving average price is $17.60.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均價格為 17.09 美元，200 日移動平均價格為 17.60 美元。</p>
</div><h2>Hedge Funds Weigh In On PureTech Health</h2>
<div class="lb-trans"><h2>對 PureTech Health 的對沖基金看法</h2>
</div><p>Large investors have recently modified their holdings of the stock. Persistent Asset Partners Ltd bought a new stake in PureTech Health in the second quarter worth $29,000. Diadema Partners LP bought a new stake in shares of PureTech Health in the 2nd quarter worth about $126,000. Pentwater Capital Management LP boosted its stake in shares of PureTech Health by 39.2% during the 1st quarter. Pentwater Capital Management LP now owns 33,560 shares of the company's stock worth $664,000 after purchasing an additional 9,449 shares during the period. Finally, Lansdowne Partners UK LLP bought a new position in PureTech Health during the 3rd quarter valued at about $260,973,000. Institutional investors own 0.04% of the company's stock.</p>
<div class="lb-trans"><p>大型投資者最近調整了對該股票的持有。Persistent Asset Partners Ltd 在第二季度購買了 PureTech Health 的新股份，價值 29,000 美元。Diadema Partners LP 在第二季度購買了 PureTech Health 的新股份，價值約 126,000 美元。Pentwater Capital Management LP 在第一季度將其在 PureTech Health 的股份增加了 39.2%。Pentwater Capital Management LP 目前擁有 33,560 股該公司的股票，價值 664,000 美元，此前在此期間又購買了 9,449 股。最後，Lansdowne Partners UK LLP 在第三季度購買了價值約 260,973,000 美元的 PureTech Health 新頭寸。機構投資者持有該公司 0.04% 的股票。</p>
</div><h2>About PureTech Health</h2>
<div class="lb-trans"><h2>關於 PureTech Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.</p>
<div class="lb-trans"><p>PureTech Health plc 從事生物技術和製藥解決方案的開發和商業化，主要在美國。該公司正在開發 LYT-100，目前處於第二階段，旨在治療特發性肺纖維化（IPF）；以及 LYT-200，一種 IgG4 單克隆抗體，目前處於 1/2 階段，針對 galectin-9 用於治療實體腫瘤和血液惡性腫瘤。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than PureTech Health</li>
<li>TSX Venture Exchange (Formerly Canadian Venture Exchange)</li>
<li>Why Taiwan Semiconductor's 6.5% Dip Could Be a Smart Buy</li>
<li>Investing in the High PE Growth Stocks</li>
<li>RTX Surges to Record Highs as Defense Orders Explode</li>
<li>Business Services Stocks Investing</li>
<li>Smart Money Is Buying Auto Suppliers, Not Car Brands</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 PureTech Health</li>
<li>TSX 風險投資交易所（前身為加拿大風險投資交易所）</li>
<li>為什麼台灣半導體的 6.5% 下跌可能是一個明智的購買</li>
<li>投資於高市盈率成長股</li>
<li>RTX 在國防訂單激增時飆升至歷史新高</li>
<li>商業服務股票投資</li>
<li>聰明資金正在購買汽車供應商，而不是汽車品牌</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in PureTech Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元於 PureTech Health 嗎？</h2>
</div><p>Before you consider PureTech Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 PureTech Health 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 PureTech Health 並不在名單上。</p>
</div><p>While PureTech Health currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 PureTech Health 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

PureTech Health（NASDAQ:PRTC）股價下跌 0.7% - 現在是賣出的時候嗎？